Biogen wins appeal for patent protection of blockbuster drug

Oct 24, 2018

Forward Pharma’s challenge to Biogen’s patent on its blockbuster multiple sclerosis medication Tecfidera has been officially thwarted.

This week, a U.S. federal appeals court upheld a March 2017 ruling protecting the patent, which will also keep Biogen from having to pay future royalties to Forward. The row over Tecfidera has centered around its active ingredient, dimethyl fumarate. Tecfidera, which is the best-selling oral medication for MS on the market, raked in about $4.2 billion in sales last year.

Forward said it is now “considering its options in response to the decision.” The company also appealed a failed patent challenge that is ongoing in the EU.  

Read the full Reuters report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments